Stopping hydroxychloroquine should almost always be done gradually and under medical supervision, because abrupt discontinuation raises the risk of disease flares, particularly in lupus and rheumatoid arthritis. The drug has an unusually long half-life of more than 40 days, which means it lingers in your body for months after you take your last dose. That slow clearance gives you a built-in buffer, but it also means that the consequences of stopping can take weeks or months to surface, making it easy to assume you’re fine right up until a flare hits. Whether you’re stopping because of side effects, eye concerns, or a stretch of stable disease, the process matters as much as the decision.
Why People Stop Hydroxychloroquine
In a study of older adults with lupus, the single most common reason for stopping hydroxychloroquine was retinal toxicity, accounting for about 42% of discontinuations. Patient preference was next at roughly 35%, followed by other side effects at around 15%.1PubMed Central. Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study That breakdown tells you something useful: most people who stop are not doing it because hydroxychloroquine quit working. They’re doing it because of what the drug does to the rest of their body over time.
Retinal toxicity is the concern that gets the most attention. The risk stays low for the first several years of use, then climbs sharply toward about 1% after five to seven years of continuous therapy, particularly at doses above 5 mg per kilogram of actual body weight per day.2PubMed. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy At very high doses, the picture looks much worse: people taking 800 to 1,000 mg daily have shown retinopathy rates of 25 to 40% within just one to two years.3The Journal of Rheumatology. Hydroxychloroquine Ocular Toxicity: A Comprehensive Review Once retinal damage is detected or strongly suspected, stopping the drug is generally recommended, though the decision should involve your rheumatologist and ophthalmologist together.
Cardiac side effects are another reason your doctor might suggest stopping. Long-term hydroxychloroquine use has been linked to QTc prolongation, cardiomyopathy, and conduction abnormalities.4PubMed Central. Hydroxychloroquine, QTc prolongation and risk of torsades de pointes Other adverse effects that might prompt discontinuation include gastrointestinal intolerance and, less commonly, restrictive cardiomyopathy or cardiac arrhythmias.5PubMed Central. QTc Prolongation with the Use of Hydroxychloroquine and Concomitant Arrhythmogenic Medications: A Retrospective Study Using Electronic Health Records Data Nausea and low blood sugar have also led to early discontinuation in clinical settings.6JAMA Cardiology. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)
The Flare Risk Is Real and Well-Documented
If you have lupus, the strongest argument for caution when stopping hydroxychloroquine is the flare data. A large study following patients in the Systemic Lupus International Collaborating Clinics cohort found that people who stopped the drug completely had a 56% higher rate of flares compared to those who stayed on it. Even just reducing the dose raised the flare rate by about 20%.7Annals of the Rheumatic Diseases. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics inception cohort Over the follow-up period, roughly 72% of people who discontinued hydroxychloroquine flared, compared to about 50% in those who continued the drug. That gap is hard to ignore.
An older but well-known randomized trial painted a similar picture: over about three and a half years, half of the patients randomized to stop hydroxychloroquine experienced a major flare, compared to 28% of those who continued.8PubMed Central. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus The relative risk of a major flare was roughly halved by staying on the drug. These weren’t just minor upticks in symptoms; the study tracked serious outcomes including nephritis and vasculitis flares.
For rheumatoid arthritis, the picture is somewhat different but the underlying principle holds. In a study of RA patients in clinical remission who tapered or stopped various medications, relapse rates ranged from about 42% in those on partial tapers to 77% in those who discontinued all treatment. Factors that predicted relapse included certain antibody markers at baseline and worsening functional disability within the first couple of months after stopping.9PubMed. Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission The takeaway for RA patients is that tapering is feasible, but it needs to be closely monitored, and certain people are at higher risk of bouncing back.
Who Is Most Vulnerable When Stopping
Not everyone faces the same risk when hydroxychloroquine is reduced or discontinued. Research has identified specific factors that make a poor outcome more likely. In lupus patients who were tapering the drug, being on prednisone at the time of the taper was independently linked to worse outcomes. Among those who stopped entirely, Black patients and those who were diagnosed with lupus at age 25 or younger faced a higher risk of problems.10PubMed Central. Predictors of Unsuccessful Hydroxychloroquine Tapering and Discontinuation: Can We Personalize Decision‐Making in Systemic Lupus Erythematosus Treatment? These findings suggest that the decision to taper or stop shouldn’t be one-size-fits-all. If you fall into a higher-risk category, your doctor may want to taper even more slowly, monitor you more frequently, or reconsider whether stopping is truly necessary right now.
The same study found that among people who stayed on hydroxychloroquine, those using other immunosuppressive drugs at baseline still had elevated risk of poor outcomes. That tells you something about baseline disease severity: if your lupus already requires multiple medications to keep quiet, pulling one out of the mix carries more weight.
Pregnancy Is a Special Case
If you’re pregnant or planning to become pregnant, the usual instinct is to stop taking anything that isn’t absolutely essential. With hydroxychloroquine, that instinct can backfire. A study tracking pregnancies in women with lupus or rheumatoid arthritis found that temporarily stopping the drug for even one to two months triggered disease flares that required relatively high doses of glucocorticoids to control.11Annals of the Rheumatic Diseases. Safety of hydroxychloroquine in pregnant women with systemic lupus erythematosus and rheumatoid arthritis The conclusion from that data was straightforward: it is generally safer to continue hydroxychloroquine during pregnancy than to stop it out of caution. The flare itself, and the steroids needed to treat it, typically pose more risk to the pregnancy than the hydroxychloroquine does. This is one of those areas where the evidence runs strongly counter to what many patients assume, and it’s worth a direct conversation with your rheumatologist and obstetrician.
Why the Long Half-Life Matters for Your Taper
Hydroxychloroquine’s pharmacology is unusual. The drug is heavily absorbed by tissues, especially the liver, spleen, kidneys, and lungs, which is why its terminal elimination half-life exceeds 40 days. After even a single dose, blood and urine samples need to be collected for roughly five months to fully characterize how the drug clears.12PubMed Central. Bioavailability of hydroxychloroquine tablets in healthy volunteers For someone who has taken it daily for years, those tissue reservoirs are saturated.
This long half-life is both a blessing and a complication. On the positive side, it means that missing a dose or even a few days won’t immediately strip you of the drug’s protective effects. Your body essentially has a deep reservoir to draw from. On the other hand, it means that when you do stop, the drug drains out very slowly, and the immune system’s response to losing it can be delayed by weeks or months. A flare that appears three months after you stop isn’t a coincidence; it’s right on schedule pharmacologically. This is also why dialysis doesn’t effectively clear hydroxychloroquine from the body. The drug is locked up in tissues, not floating freely in the blood where a dialysis machine can grab it.
For practical purposes, this means that a taper is partly symbolic at the tissue level. Your body is going to wean itself off the drug gradually no matter what you do, because the stored drug takes so long to leave. But a taper still matters because it adjusts the rate at which your daily blood levels fall, which gives your immune system a smoother transition. A common approach is cutting the dose in half for several weeks or months, then taking the drug every other day for a period before stopping altogether. There’s no single universal protocol, and the timeline should be adapted to your disease activity, your reason for stopping, and how long you’ve been on the drug.
Kidney Function Changes the Equation
Hydroxychloroquine is primarily cleared through the kidneys. If your kidney function is impaired, the drug accumulates faster and clears more slowly, which increases the risk of toxicity, particularly cardiac toxicity. Guidelines suggest reducing the dose by about 50% in patients with significant kidney impairment, and adjustments should account for the specific type of dialysis if you’re on it.13Journal of Pharmaceutics and Pharmacology Research. Hydroxychloroquine and chronic renal failure Notably, dialysis itself does not meaningfully lower plasma concentrations of hydroxychloroquine, so if toxicity develops, simply adding dialysis sessions won’t quickly solve the problem. For people with declining kidney function who are being taken off the drug, the long washout period can actually mean prolonged exposure to higher-than-intended levels even after the last pill.
What to Expect After You Stop
Some side effects of hydroxychloroquine resolve predictably after discontinuation. Skin hyperpigmentation, a bluish-gray discoloration that can appear on the shins, face, or hard palate, typically fades within about six months, though it occasionally persists longer.14PubMed Central. Hydroxychloroquine-induced hyperpigmentation in a 14-year-old female with systemic lupus erythematosus Gastrointestinal side effects like nausea tend to improve more quickly since they’re related to the active drug in your system rather than tissue stores.
Retinal damage, however, does not reliably reverse. Once hydroxychloroquine has damaged the retina, stopping the drug prevents further progression but does not restore lost function. In some cases, retinopathy can even continue to worsen for a period after discontinuation because of the drug still present in retinal tissue. This is why screening guidelines recommend detecting toxicity early, before you notice any visual changes yourself. By the time you see a problem, the damage may be more advanced than it appears on initial testing.
Cardiac effects occupy a middle ground. QTc prolongation tends to improve after the drug is stopped, but structural changes like cardiomyopathy may be only partially reversible depending on how long they’ve been developing. If you were taken off hydroxychloroquine for cardiac reasons, your doctor will likely want to monitor your heart rhythm and function for several months after discontinuation to track improvement.
Monitoring After Discontinuation
Once you’ve stopped, the monitoring schedule depends on why you were on the drug and why you came off it. For lupus patients, the first six months are the most critical window for flares. Your rheumatologist will likely want to see you more frequently during this period, checking labs and clinical markers for signs that your disease is waking up. The SLICC cohort data showed that flares were common across the follow-up period but that the rate was highest relatively soon after discontinuation.7Annals of the Rheumatic Diseases. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics inception cohort
For rheumatoid arthritis patients, early indicators of relapse can include ultrasound evidence of joint inflammation reappearing within the first three months, even before you feel anything clinically. That study found relapse rates were significantly higher in patients whose ultrasound scores rose within the first three months of stopping medication.9PubMed. Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission If your rheumatologist has access to musculoskeletal ultrasound, it can serve as an early warning system.
If you stopped because of retinal toxicity, ongoing eye exams remain important. Your ophthalmologist will want to confirm that the retinopathy has stabilized and is not progressing further despite discontinuation. Annual screenings typically continue for at least a couple of years.
The Psychology of Stopping
There’s an emotional dimension to discontinuing hydroxychloroquine that doesn’t get discussed enough in clinical settings. The drug became a lightning rod during the early COVID-19 pandemic, and the resulting supply disruptions caused real psychological harm to patients who depend on it. A survey of over 2,000 lupus patients found that more than a quarter reported extremely high anxiety levels during the initial shortage period. Even after supply improved, patients continued to report elevated anxiety, suggesting the experience left a lasting mark on how they relate to the medication.15PubMed Central. Hydroxychloroquine availability during COVID-19 crisis and its effect on patient anxiety
If you’re stopping hydroxychloroquine by choice, a different kind of anxiety may show up: the worry that your disease will return without its protective effects. That worry is reasonable given the flare data described above, and it’s worth naming it rather than pushing past it. Ask your rheumatologist what the plan is if a flare does occur. Knowing that there’s a backup strategy, whether it’s restarting hydroxychloroquine, adding a different immunosuppressant, or temporarily increasing steroids, can make the transition less stressful. Some patients who were taken off the drug for eye concerns ask whether it’s possible to restart at a lower dose. The answer depends on the severity of retinal findings and the severity of the underlying disease, but it’s a conversation worth having.
When Self-Tapering Goes Wrong
A significant proportion of hydroxychloroquine discontinuations are patient-initiated rather than doctor-directed. As that older-adult study showed, patient preference alone accounted for roughly a third of all stops.1PubMed Central. Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study Some people feel well and decide they no longer need the drug. Others are frustrated by side effects and stop without telling their doctor. Still others run out and don’t refill.
The problem with self-tapering isn’t just the flare risk. It’s that nobody is watching. If you stop on your own and a flare develops gradually over two or three months, you might attribute the creeping fatigue, joint pain, or skin changes to something else entirely, and delay seeking care. The long half-life creates a false sense of security in the early weeks. You feel fine, so you assume the drug wasn’t doing much. Then the tissue stores deplete and the immune system starts testing boundaries.
If you’re thinking about stopping, bring it up at your next appointment. If cost, side effects, or inconvenience is driving the decision, your doctor may have solutions that don’t require discontinuation: a dose reduction, a switch from tablets to a different formulation, or better management of gastrointestinal symptoms. The worst-case scenario is stopping silently and then presenting months later with organ-threatening disease activity that could have been caught early.
Restarting After a Break
If you stopped hydroxychloroquine and then need to restart it, the ramp-up is generally straightforward. Most clinicians resume at the target dose rather than gradually increasing, since the drug takes weeks to build back up in tissues anyway. The main concern with restarting is whether the reason you stopped has been adequately addressed. If you stopped for retinal toxicity, restarting requires careful ophthalmologic reassessment and possibly a lower dose. If you stopped during pregnancy, resuming postpartum is typically encouraged, since the drug’s benefits extend to breastfeeding and long-term disease control.
For people who stopped because they felt well and then flared, restarting usually works. The drug doesn’t lose its effectiveness because you took a break. But the flare itself may take time to bring back under control, and you may need temporary corticosteroids or other medications to bridge the gap while hydroxychloroquine rebuilds its tissue levels. That bridge period is a reminder of why the taper-and-monitor approach is safer than an abrupt stop: you give the system time to adjust without leaving yourself unprotected.